Lumigan vs Latisse
A question that we get asked frequently is “what is the difference between Mylash and Latisse?”
The short answer is that they are both the same treatment.
The long answer is due to the origin of the treatment.
Bimatoprost 0.03% ophthalmic solution was originally used under the name Lumigan as an eyedrop to treat glaucoma, a condition in which the pressure within your eyeball is too high. It was applied at least once a day over a prolonged period and was used by millions of patients.
A well documented side effect of this treatment was eyelash growth. The treatment is a prostaglandin analogue and it has since been found that these can act to stimulate the hair growth cycle, resulting in hair that is longer, thicker and darker. This resulted in many patients growing long thick eyelashes which were very noticeable. Some people did not necessarily find this a bad side effect and others desired the results that the treatment provided.
In 2008, the American FDA gave approval for the cosmetic use of bimatoprost 0.03% under the name Latisse. The ingredients are the same as Lumigan, as are the concentrations of all the ingredients and the bottle that it is supplied in. The only difference is the packaging and that it is supplied with applicators.
To gain FDA approval the safety profile of the treatment had to be studied. Luckily there was years of data on the use of the liquid directly on the eye and they found that there was significantly less side effects when applied to the skin, possibly due to the lower dose used as it is a smaller area and because the skin is less sensitive. The results were also documented and it was found that the average trial participant grew eyelashes that were 25% longer, 106% thicker and 18% darker.
Written by Dr Tom Walker